Glaxo's opportunity more apparent than real?

Just because a disease indication is large doesn't mean that a product will find a significant market. Such may be the case with Glaxo Wellcome's new Zanamivir neuraminidase inhibitor, which is the first compound in its class to show evidence of clinical efficacy against influenza.

The compound achieved a statistically significant reduction in days of symptoms from 5 to 4 in a Phase II trial (see Clinical Results, B10).